Boehringer Ingelheim

For Healthcare Professionals

Logout

Boehringer Ingelheim

Boehringer Ingelheim

Boehringer Ingelheim

Therapeutic Area
Therapeutic Area

At Boehringer Ingelheim we are driven by the desire to serve mankind by improving human and animal health. As a successful, family owned company we plan in generations. We work together globally and with integrity. Our Focus articulates who we are and what we strive for, how we work and what we want to achieve.

Section Overview

Therapeutic Area

Section Overview

Cardiovascular

Metabolic

Inflammation

Respiratory
Products
Products

Boehringer Ingelheim is a research-driven group of companies dedicated to the discovery, development, manufacture and marketing of innovative health care products.

See all products

Products

See all products
Resources
Contact
Logout

Boehringer Ingelheim

Empagliflozin

Iinagliptin

Format

Sort by

Reset all filters

Exper's Video Prof Zieroth Value of GDMT to achieve outcomes in CRM

2:07

Expert's Video Prof. Zieroth Value of GDMT to achieve outcomes in CRM

Watch now Opens in new tab

Expert's Video Prof. Zieroth Addressing hurdles in adopting CRM Management

2:01

Expert's Video Prof. Zieroth Addressing hurdles in adopting CRM Management

Watch now Opens in new tab

Expert's Video Prof Zieroth Adhering to early and sustained treatment

1:03

Expert's Video Prof. Zieroth Adhering to early and sustained treatment

Watch now Opens in new tab

Prof Januzzi Snippet-How safe of Empagliflozin Jardiance in HFrEF

1:32

Prof. Januzzi Snippet-How safe of Empagliflozin Jardiance in HFrEF

Watch now Opens in new tab

What is the Mechanism of Jardiance in HF - Prof. Januzzi

2:46

What is the Mechanism of Jardiance in HF - Prof. Januzzi

Watch now Opens in new tab

Home
Metabolic
Empagliflozin

Sitemap

Therapeutic Area

Resources
- Videos
- Clinical studies

BI logo

Privacy
Terms of use
Sitemap
Contact

Copyright © 2025 Boehringer Ingelheim (Philippines), Inc. All rights reserved. Use of this Site is subject to the Terms of Use and Privacy Statement. Prepared June 2025